MI
MDGL icon

Motiv8 Investments’s Madrigal Pharmaceuticals MDGL Stock Holding History

Motiv8 Investments’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6K Buy
+10
New +$5.11K ﹤0.01% 528

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Motiv8 Investments's MDGL Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Madrigal Pharmaceuticals (MDGL) in Q4 2025: 10 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #528 among its holdings.

387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Motiv8 Investments held 10 shares of Madrigal Pharmaceuticals worth $6K as of Q4 2025.
  • Madrigal Pharmaceuticals was a new Motiv8 Investments position in Q4 2025.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #528 holding.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.